Main Article Content
arrhythmia, antiarrhythmic drugs, beta-blockers, amiodarone, clinical pharmacy
Background: Antiarrhythmic drugs are commonly used to treat arrhythmia. However, data on the usage pattern of antiarrhythmic drugs, associated side effects, and the role of clinical pharmacist interventions in the Middle East are scarce. Objective: The purpose of this study was to describe the usage pattern, side effects, and clinical pharmacist interventions of antiarrhythmic drugs at the Sultan Qaboos University Hospital (SQUH), a tertiary care hospital in Oman. Methods: This retrospective observational study included adult patients (≥18 years) who received at least one dose of antiarrhythmic drugs at SQUH between January 2020 and December 2021. Ethical approval was obtained prior to conducting the study. Results: In total, 400 patients were enrolled in this study. Their mean age was 62.5 ± 16.6 years (range:19-96), and 55.3% (221/400) were male. Atrial arrhythmias were the most commonly observed (344/400, 86.0%). Beta-blockers (337/500, 67.4%) were the most prescribed class of drugs. The most commonly prescribed drugs were bisoprolol (263/400, 65.8%), carvedilol (65/400, 16.3%), and amiodarone (59/400, 14.8%). The majority of patients (300/400, 75.0%) received monotherapy, whereas 25% (100/400) received combination therapy. A total of 109 side effects were reported in 45 patients, resulting in an incidence rate of 11.3 %, with cardiovascular side effects accounting for the majority (41/109, 37.6%) of these. Amiodarone had the highest prevalence of adverse effects (33/109, 30.3%). A total of 122 clinical pharmacist interventions were observed in 13.0 % (52/400) of patients. Beta-blockers were associated with more than half of the interventions (61/122, 50.0%). Age (61.84 years vs. 66.75 years; p=0.047), comorbidities (83.6% vs. 96.2%; p=0.019), renal impairment (19.6% vs. 40.4%; p=0.001, heart failure (11.8% vs. 28.9%; p=0.002), concomitant medications (84.5% vs. 98.1%; p=0.004), polypharmacy (51.1% vs. 69.2%; p=0.022) and duration of therapy of less than one year (9.3% vs. 27.3%; p<0.001) was significantly associated with the need for intervention. Conclusion: Beta-blockers were the most commonly prescribed antiarrhythmic drugs in SQUH. Amiodarone was associated with the highest prevalence of side effects. Clinical pharmacy intervention at the SQUH was mainly related to antiarrhythmic drug selection and dose optimization.
2. Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: Systematic review and meta-analysis. BMJ. 2016;354:i4482.
3. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158(3):229-234. https://doi.org/10.1001/archinte.158.3.229
4. Kang Y, Bahler R. Health-related quality of life in patients newly diagnosed with atrial fibrillation. Eur J Cardiovasc Nurs. 2004;3(1):71-6. https://doi.org/10.1016/j.ejcnurse.2003.12.002
5. Mankad P, Kalahasty G. Antiarrhythmic drugs. Medical Clinics of North America. 2019;103(5):821-834. https://doi. org/10.1016/j.mcna.2019.05.004
6. Nogami A, Kurita T, Kusano K, et al. Japanese Circulation Society / the Japanese Heart Rhythm Society Joint Working Group. JCS/JHRS 2021 guideline focused update on non-pharmacotherapy of cardiac arrhythmias. J Arrhythm. 2022;38(1):1-30.
7. Raj GM. Drugs Used in Cardiac Arrhythmias. In: Paul A, Anandabaskar N, Mathaiyan J, Raj GM. 2021 (eds) Introduction to Basics of Pharmacology and Toxicology. Springer, Singapore. https://doi.org/10.1007/978-981-33-6009-9_27
8. Barton AK, McGowan M, Smyth A, et al. Classification and choice of antiarrhythmic therapies. Prescriber. 2020;31:11-17. https://doi.org/10.1002/psb.1828
9. Markman TM, Geng Z, Epstein AE, et al. Trends in antiarrhythmic drug use among patients in the United States between 2004 and 2016. Circulation. 2020;141(11):937-939. https://doi.org/10.1161/circulationaha.119.044109
10. Poulsen CB, Damkjær M, Løfgren B, et al. Trends in Antiarrhythmic Drug Use in Denmark Over 19 Years. Am J Cardiol. 2020;125(4):562-569. https://doi.org/10.1016/j.amjcard.2019.11.009
11. Tardos JG, Ronk CJ, Patel MY, et al. US Antiarrhythmic Drug Treatment for Patients with Atrial Fibrillation: An Insurance Claims- Based Report. J Am Heart Assoc. 2021;10(6):e016792. https://doi.org/10.1161/JAHA.120.016792
12. Chiang CE, Goethals M, O’Neill JO, et al. RealiseAF survey investigators. Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibrillation in a large contemporary international survey: insights from RealiseAF. Europace.
13. Allen LaPointe NM, Dai D, Thomas L, et al. Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease. Am J Cardiol. 2015;115(3):316-322. https://doi.org/10.1016/j.amjcard.2014.11.005
14. Snider M, Kalbfleisch S, Carnes CA. Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review. Clin Ther. 2009;31(6):1209-1218. https://doi.org/10.1016/j.clinthera.2009.06.014
15. Freeland S, Worthy C, Zolnierz M. Initiation and monitoring of class III antiarrhythmic agents. J Cardiovasc Electrophysiol. 2003;14(12 Suppl):S291-295. https://doi.org/10.1046/j.1540-8167.2003.90406.x
16. Long VP III, Carnes CA, Vecchiet J, et al. Evaluation of a pharmacist-managed electrolyte protocol in outpatients on antiarrhythmic medications. J Am Pharm Assoc (2003). 2017;57(4):526-531. https://doi.org/10.1016/j.japh.2017.05.001
17. Al Salmi Z. Clinical Audit of Pharmaceutical Care provided by a Clinical Pharmacist in Cardiology and Infectious Disease inpatients at the Royal Hospital, Muscat/Oman. Oman Med J. 2009;24(2):89-94. https://doi.org/10.5001/omj.2009.21
18. Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task
Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. https://
19. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart
Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):e91-e220. https://doi.org/10.1016/j.jacc.2017.10.054
20. Zubaid M, Rashed WA, Alsheikh-Ali AA, et al. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Investigators. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE): design and baseline characteristics of patients with atrial fibrillation in the Arab Middle
East. Circ Cardiovasc Qual Outcomes. 2011;4(4):477-482. https://doi.org/10.1161/CIRCOUTCOMES.110.959700
21. Humphries KH, Kerr CR, Steinbuch M, et al. Canadian Registry of Atrial Fibrillation investigators. Limitations to antiarrhythmic drug use in patients with atrial fibrillation. CMAJ. 2004;171(7):741-745. https://doi.org/10.1503/cmaj.1031277
22. Andrade JG, Connolly SJ, Dorian P, et al. Antiarrhythmic use from 1991 to 2007: insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). Heart Rhythm. 2010;7(9):1171-1177. https://doi.org/10.1016/j.hrthm.2010.04.026
23. Zimetbaum P, Ho KK, Olshansky B, et al. FRACTAL Investigators. Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation. Am J Cardiol. 2003;91(1):81-83. https://doi.org/10.1016/s0002-9149(02)03004-7
24. Reiffel JA. Oral Anticoagulation and Antiarrhythmic Drug Therapy for Atrial Fibrillation. J Innov Card Rhythm Manag. 2018;9(12):3446-3452. https://doi.org/10.19102/icrm.2018.091201
25. Olimpieri PP, Di Lenarda A, Mammarella F, et al. Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: Insights from Italian monitoring registries. Int J Cardiol Heart Vasc. 2020;26:100465. https://doi.org/10.1016/j.
26. Roldán Rabadán I, Anguita Sánchez M, Marín F, et al. FANTASIIA study researchers. Current Antiarrhythmic Therapy for Nonvalvular Atrial Fibrillation in Spain. Data from the FANTASIIA Registry. Rev Esp Cardiol (Engl Ed). 2016;69(1):54-60. https://
27. Zubaid M, Rashed WA, Alsheikh-Ali AA, et al. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Investigators. Management and 1-year outcomes of patients with atrial fibrillation in the Middle East: Gulf survey of atrial fibrillation events. Angiology.
28. Grandi E, Ripplinger CM. Antiarrhythmic mechanisms of beta blocker therapy. Pharmacol Res. 2019;146:104274. https://doi. org/10.1016/j.phrs.2019.104274
29. Dorian P, Angaran P. β-Blockers and atrial fibrillation: hypertension and other medical conditions influencing their use. Can J Cardiol. 2014;30(5 Suppl):S38-41. https://doi.org/10.1016/j.cjca.2013.09.029
30. Muresan L, Cismaru G, Muresan C, et al. Beta-blockers for the treatment of arrhythmias: Bisoprolol - a systematic review. Ann Pharm Fr. 2022;80(5):617-634. https://doi.org/10.1016/j.pharma.2022.01.007
31. Rosca CI, Kundnani NR, Tudor A, et al. Benefits of prescribing low-dose digoxin in atrial fibrillation. Int J Immunopathol Pharmacol. 2021;35:20587384211051955. https://doi.org/10.1177/20587384211051955
32. Benito L, Hoyo J, Montroig A, et al. Adverse effects of antiarrhythmic drugs in patients with atrial fibrillation in primary care. Med Clin (Barc). 2011;137(6):241-246. https://doi.org/10.1016/j.medcli.2010.06.034
33. Kawabata M, Yokoyama Y, Sasaki T, et al. Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers. Clin Pharmacol. 2015;7:29-36. https://doi.org/10.2147/CPAA.S77021
34. Jackevicius CA, Tom A, Essebag V, et al. Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am J Cardiol. 2011;108(5):705-710. https://doi.org/10.1016/j.amjcard.2011.04.024
35. Al-Baghdadi H, Koca Al-Baghdadi Ç, Abdi A, et al. Introducing clinical pharmacy services to cardiovascular clinics at a university hospital in Northern Cyprus. Int J Clin Pharm. 2017;39(6):1185-1193. https://doi.org/10.1007/s11096-017-0534-3
36. Mangoni AA, Jarmuzewska EA. The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence. Br J Clin Pharmacol. 2019;85(1):20-36. https://doi.org/10.1111/bcp.13760
37. Ding WY, Potpara TS, Blomström-Lundqvist C, et al. ESC-EHRA EORP-AF Long-Term General Registry Investigators. Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry. Eur J Clin Invest. 2022;52(6):e13745.
38. Gallagher C, Nyfort-Hansen K, Rowett D, et al. Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2020;7(1):e001257. https://doi.org/10.1136/openhrt-2020-001257
39. Alderman CP, Farmer C. A brief analysis of clinical pharmacy interventions undertaken in an Australian teaching hospital. J Qual Clin Pract. 2001;21(4):99-103. https://doi.org/10.1046/j.1440-1762.2001.00428.x